Beth Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beth Han has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Wilson M. Compton
National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland
20 shared publications- Carlos Blanco
National Institute on Drug Abuse, Bethesda, USA
10 shared publications - Wilson M. Compton
National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA
10 shared publications Christopher M. Jones
Substance Abuse and Mental Health Services Administration, Rockville, US
9 shared publicationsEmily B. Einstein
National Institute on Drug Abuse, National Institutes of Health, Bethesda, US
8 shared publicationsRichard McKeon
Substance Abuse and Mental Health Services Administration, Rockville, MD
6 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Springer Nature in Molecular Psychiatry
- p. 1-13
Polysubstance use disorders among US adults
Polysubstance use disorders ( ≥ 2 substance use disorders (SUDs)) are associated with high morbidity and mortality. We analyzed data from 92,233 adult participants in the 2022–2023 US National Surveys on Drug Use and Health to estimate past-year prevalence of polysubstance use disorders and to examine their associations with age of substance use initiation. Multivariable logistic regression and Poisson regression were applied. Age- and sex-adjusted past-year prevalence of 2 SUDs was 19.2–44.9% (95% CIs=11.1–62.3%) among adults with any SUD. Age- and sex-adjusted past-year prevalence of ≥3 SUDs ranged from 16.4% (95% CI = 14.3–18.6%) among adults with cannabis use disorder, to 32.4–44.7% (95% CIs=29.1–51.3%) among those with opioid use disorder or prescription stimulant or tranquilizer/sedative use disorder, and up to 48.2–72.0% (95% CIs=39.4–81.7%) among those with methamphetamine, cocaine, or hallucinogen use disorder. Overall, compared to adults who initiated substance use before age 18, the number of SUDs was 73–83% lower for those who initiated at age ≥21 (range of incidence density ratios (IDRs)=0.17–0.27, 95% CIs=0.12–0.31). Specifically, compared with corresponding adult counterparts who initiated before age 18, the number of moderate-severe SUDs was 32% lower among those initiating alcohol at ages 21–29 (IDR = 0.68, 95% CI = 0.57–0.83), 21% lower among those initiating cannabis at ages 21–29 (IDR = 0.79, 95% CI = 0.69–0.90), and 45–62% lower (IDRs=0.38–0.55, 95% CIs=0.31–0.76) among adults who never initiated alcohol, cannabis, or nicotine use. The elevated prevalence of polysubstance use disorders associated with early initiation of substance use underscores the critical need for evidence-based strategies to prevent alcohol, cannabis, and nicotine consumption before age 21.
- 29 April 2026
- Published by Springer Nature in Molecular Psychiatry
- p. 1-13
Open AccessPolysubstance use disorders among US adults
Polysubstance use disorders ( ≥ 2 substance use disorders (SUDs)) are associated with high morbidity and mortality. We analyzed data from 92,233 adult participants in the 2022–2023 US National Surveys on Drug Use and Health to estimate past-year prevalence of polysubstance use disorders and to examine their associations with age of substance use initiation. Multivariable logistic regression and Poisson regression were applied. Age- and sex-adjusted past-year prevalence of 2 SUDs was 19.2–44.9% (95% CIs=11.1–62.3%) among adults with any SUD. Age- and sex-adjusted past-year prevalence of ≥3 SUDs ranged from 16.4% (95% CI = 14.3–18.6%) among adults with cannabis use disorder, to 32.4–44.7% (95% CIs=29.1–51.3%) among those with opioid use disorder or prescription stimulant or tranquilizer/sedative use disorder, and up to 48.2–72.0% (95% CIs=39.4–81.7%) among those with methamphetamine, cocaine, or hallucinogen use disorder. Overall, compared to adults who initiated substance use before age 18, the number of SUDs was 73–83% lower for those who initiated at age ≥21 (range of incidence density ratios (IDRs)=0.17–0.27, 95% CIs=0.12–0.31). Specifically, compared with corresponding adult counterparts who initiated before age 18, the number of moderate-severe SUDs was 32% lower among those initiating alcohol at ages 21–29 (IDR = 0.68, 95% CI = 0.57–0.83), 21% lower among those initiating cannabis at ages 21–29 (IDR = 0.79, 95% CI = 0.69–0.90), and 45–62% lower (IDRs=0.38–0.55, 95% CIs=0.31–0.76) among adults who never initiated alcohol, cannabis, or nicotine use. The elevated prevalence of polysubstance use disorders associated with early initiation of substance use underscores the critical need for evidence-based strategies to prevent alcohol, cannabis, and nicotine consumption before age 21.
- Open Access
United States trends in non‐prescribed use of Adderall and Ritalin: Population Assessment of Tobacco and Health (PATH) Study estimates from 2013 to 2022
Background and Aims: Dispensing of prescription stimulants to adults has risen dramatically over the past decade. Examining trends in nonprescribed use of prescription stimulants can inform public health responses. Most studies in the United States (U.S.) have faced challenges in assessing trends over time due to changes in survey methodologies and variation in populations assessed. We examined data from the Population Assessment of Tobacco and Health (PATH) Study to assess changes in nonprescribed use of prescription stimulants in the U.S. from 2013 to 2022.Design: The PATH Study is an ongoing longitudinal study of U.S. youth and adults, representative of the civilian noninstitutionalized population. Repeated cross‐sectional estimates at each wave were used (8 total waves). Trends from Wave (W) 1 (September 2013–December 2014) to W7 (January 2022–April 2023) were assessed. Full‐sample and replicate weights were used; joinpoint analyses and wave‐to‐wave comparisons were applied to test trends.Setting: Civilian noninstitutionalized U.S. youth and adults.Participants/Cases: Youth aged 12–17 and adults aged 18 + were assessed, with a total of 45 727 participants at wave 1 (Ns vary by wave).Measurements: Past 12‐month (P12M) prevalence of nonprescribed use of Ritalin or Adderall was assessed. Nonprescribed use of stimulants was assessed across subgroups according to age (12–17, 18–24, 25–39, ≥40) and sex (male, female).Findings: While wave‐to‐wave comparisons showed fluctuations across certain waves, overall, there were no statistically significant changes in P12M prevalence of Ritalin or Adderall nonprescribed use (1.3% at W1 and 1.5% at W7) across the study period. However, statistically significant differences in trends existed across age groups. Among 12–17 year‐olds, nonprescribed use prevalence remained stable (1.4% in W1 and 1.5% in W7). Nonprescribed use prevalence also remained stable for 18–24‐year‐olds from W1 to W3, but then significantly declined (p = 0.016) from W3 (5.3%) to W7 (2.6%). There were no significant changes in nonprescribed use prevalence among 25–39‐year‐olds (1.7% in W1 and 2.4% in W7) and those aged ≥40 (0.3% in W1 and 0.9% in W7). Across most waves, young adults aged 18–24 had a statistically significantly higher prevalence of nonprescribed use. Neither sex had significant trends in P12M nonprescribed use prevalence.Conclusions: Despite an increase in dispensing of prescription stimulant medications in the United States, the prevalence of nonprescribed Ritalin or Adderall use does not appear to have increased, as assessed in the nationally representative Population Assessment of Tobacco and Health (PATH) Study. The prevalence of nonprescribed Ritalin or Adderall use among young adults aged 18–24, the age group with the highest nonprescribed use prevalence, declined 2013 to 2022.
Open AccessUnited States trends in non‐prescribed use of Adderall and Ritalin: Population Assessment of Tobacco and Health (PATH) Study estimates from 2013 to 2022
Background and Aims: Dispensing of prescription stimulants to adults has risen dramatically over the past decade. Examining trends in nonprescribed use of prescription stimulants can inform public health responses. Most studies in the United States (U.S.) have faced challenges in assessing trends over time due to changes in survey methodologies and variation in populations assessed. We examined data from the Population Assessment of Tobacco and Health (PATH) Study to assess changes in nonprescribed use of prescription stimulants in the U.S. from 2013 to 2022.Design: The PATH Study is an ongoing longitudinal study of U.S. youth and adults, representative of the civilian noninstitutionalized population. Repeated cross‐sectional estimates at each wave were used (8 total waves). Trends from Wave (W) 1 (September 2013–December 2014) to W7 (January 2022–April 2023) were assessed. Full‐sample and replicate weights were used; joinpoint analyses and wave‐to‐wave comparisons were applied to test trends.Setting: Civilian noninstitutionalized U.S. youth and adults.Participants/Cases: Youth aged 12–17 and adults aged 18 + were assessed, with a total of 45 727 participants at wave 1 (Ns vary by wave).Measurements: Past 12‐month (P12M) prevalence of nonprescribed use of Ritalin or Adderall was assessed. Nonprescribed use of stimulants was assessed across subgroups according to age (12–17, 18–24, 25–39, ≥40) and sex (male, female).Findings: While wave‐to‐wave comparisons showed fluctuations across certain waves, overall, there were no statistically significant changes in P12M prevalence of Ritalin or Adderall nonprescribed use (1.3% at W1 and 1.5% at W7) across the study period. However, statistically significant differences in trends existed across age groups. Among 12–17 year‐olds, nonprescribed use prevalence remained stable (1.4% in W1 and 1.5% in W7). Nonprescribed use prevalence also remained stable for 18–24‐year‐olds from W1 to W3, but then significantly declined (p = 0.016) from W3 (5.3%) to W7 (2.6%). There were no significant changes in nonprescribed use prevalence among 25–39‐year‐olds (1.7% in W1 and 2.4% in W7) and those aged ≥40 (0.3% in W1 and 0.9% in W7). Across most waves, young adults aged 18–24 had a statistically significantly higher prevalence of nonprescribed use. Neither sex had significant trends in P12M nonprescribed use prevalence.Conclusions: Despite an increase in dispensing of prescription stimulant medications in the United States, the prevalence of nonprescribed Ritalin or Adderall use does not appear to have increased, as assessed in the nationally representative Population Assessment of Tobacco and Health (PATH) Study. The prevalence of nonprescribed Ritalin or Adderall use among young adults aged 18–24, the age group with the highest nonprescribed use prevalence, declined 2013 to 2022.
Prevalence of cannabis consumption methods among people with medically recommended and nonmedical cannabis use in the United States
Aims: Some cannabis consumption methods (e.g. smoking, vaping, dabbing) are associated with more harms than others (e.g. sublingual, transdermal). We aimed to examine differences in prevalence of cannabis consumption methods by people with medically recommended‐only vs. nonmedical‐only cannabis use.Design and setting: Cross‐sectional, US nationally representative data from the 2022 National Survey on Drug Use and Health (NSDUH).Participants: 14 271 NSDUH participants aged ≥12 with past‐year cannabis use.Measurements: NSDUH asked respondents with past‐year cannabis use about their consumption methods [i.e. smoking, vaping, eating or drinking, dabbing (consuming a concentrated form with a dab rig/pen), oral/sublingual, transdermal or taking pills] and if healthcare professionals recommended any cannabis use. If ‘no’, respondents were classified as having ‘nonmedical‐only cannabis use’. If ‘yes’, they were asked if all cannabis use was recommended and, if so, they were classified as having ‘medically recommended‐only cannabis use’; otherwise, they were classified as having ‘medical and nonmedical cannabis use’.Findings: Among people reporting cannabis use, 10.7% [95% confidence interval (CI) = 9.7%–11.7%] reported medically recommended‐only use, and 83.0% (95% CI = 81.7%–84.3%) reported nonmedical‐only use. Smoking was the predominant method for nonmedical‐only use (79.2%, 95% CI = 77.7%–80.7%) and for medically recommended‐only use (73.7%, 95% CI = 68.8%–78.2%). Vaping prevalence (45.6%, 95% CI = 40.9%–50.4%) and eating/drinking prevalence (45.7%, 95% CI = 40.7%–50.7%) were similar among people with medically recommended‐only use. Vaping prevalence was 1.3 times higher [adjusted prevalence ratio (APR) = 1.3, 95% CI = 1.2–1.4] for medically recommended‐only than for nonmedical‐only use (38.3%, 95% CI = 32.7%–44.3%). Dabbing prevalence was 1.5 times higher (APR = 1.5, 95% CI = 1.3–1.7) for medically recommended‐only than for nonmedical‐only use [24.4% (95% CI = 20.5%–28.8%) vs 16.4% (95% CI = 15.3%–17.7%)]. Higher prevalence of oral/sublingual and transdermal methods was associated with medically recommended‐only use.Conclusions: Among people with past‐year medically recommended‐only cannabis use in the US, three‐fourths reported smoking cannabis and almost half reported vaping and eating/drinking cannabis. Cannabis vaping prevalence and dabbing prevalence were 1.3–1.5 times higher, respectively, among people with medically recommended‐only use than people with nonmedical‐only use.
Prevalence of cannabis consumption methods among people with medically recommended and nonmedical cannabis use in the United States
Aims: Some cannabis consumption methods (e.g. smoking, vaping, dabbing) are associated with more harms than others (e.g. sublingual, transdermal). We aimed to examine differences in prevalence of cannabis consumption methods by people with medically recommended‐only vs. nonmedical‐only cannabis use.Design and setting: Cross‐sectional, US nationally representative data from the 2022 National Survey on Drug Use and Health (NSDUH).Participants: 14 271 NSDUH participants aged ≥12 with past‐year cannabis use.Measurements: NSDUH asked respondents with past‐year cannabis use about their consumption methods [i.e. smoking, vaping, eating or drinking, dabbing (consuming a concentrated form with a dab rig/pen), oral/sublingual, transdermal or taking pills] and if healthcare professionals recommended any cannabis use. If ‘no’, respondents were classified as having ‘nonmedical‐only cannabis use’. If ‘yes’, they were asked if all cannabis use was recommended and, if so, they were classified as having ‘medically recommended‐only cannabis use’; otherwise, they were classified as having ‘medical and nonmedical cannabis use’.Findings: Among people reporting cannabis use, 10.7% [95% confidence interval (CI) = 9.7%–11.7%] reported medically recommended‐only use, and 83.0% (95% CI = 81.7%–84.3%) reported nonmedical‐only use. Smoking was the predominant method for nonmedical‐only use (79.2%, 95% CI = 77.7%–80.7%) and for medically recommended‐only use (73.7%, 95% CI = 68.8%–78.2%). Vaping prevalence (45.6%, 95% CI = 40.9%–50.4%) and eating/drinking prevalence (45.7%, 95% CI = 40.7%–50.7%) were similar among people with medically recommended‐only use. Vaping prevalence was 1.3 times higher [adjusted prevalence ratio (APR) = 1.3, 95% CI = 1.2–1.4] for medically recommended‐only than for nonmedical‐only use (38.3%, 95% CI = 32.7%–44.3%). Dabbing prevalence was 1.5 times higher (APR = 1.5, 95% CI = 1.3–1.7) for medically recommended‐only than for nonmedical‐only use [24.4% (95% CI = 20.5%–28.8%) vs 16.4% (95% CI = 15.3%–17.7%)]. Higher prevalence of oral/sublingual and transdermal methods was associated with medically recommended‐only use.Conclusions: Among people with past‐year medically recommended‐only cannabis use in the US, three‐fourths reported smoking cannabis and almost half reported vaping and eating/drinking cannabis. Cannabis vaping prevalence and dabbing prevalence were 1.3–1.5 times higher, respectively, among people with medically recommended‐only use than people with nonmedical‐only use.
- Open Access
- 14 August 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (8) , 1067
Household Compositions and Substance Use among Young Adults in the U.S.
Background: Adults aged 21–29 have the highest past-month prevalence of tobacco, alcohol, and illicit drug use in the U.S. Currently, young adults often delay traditional adulthood milestones (e.g., marriage and childbearing), which may impact their household composition and substance use. Methods: We examined how the past-month prevalence of eight mutually exclusive substance use outcomes varied by household composition among young adults using the 2016–2019 National Surveys on Drug Use and Health (NSDUH) data. Bivariable and multivariable multinomial logistic regression analyses were applied. Results: Among young adults residing with their children, the most common household composition was residing with children and a spouse/partner (16.6%, 95% CI = 16.5–16.8%). Among those residing without children, common household compositions included residing with parents (22.8%, 95% CI = 22.2–23.4%) and residing only with a spouse/partner (17.9%, 95% CI = 17.6–18.3%). Past-month prevalence of binge alcohol, tobacco, and illicit drug use varied by household composition. Residing only with children and a spouse/partner was associated with a low prevalence of most examined substance use patterns. Across household compositions, those residing solely with unrelated individuals had the highest adjusted prevalence of tobacco, drug, and binge alcohol use (13.8%, 95% CI = 12.5–15.1%). Conclusions: The prevalence of substance use patterns among U.S. young adults varies by household composition. Those residing solely with unrelated individuals had the highest prevalence of tobacco, binge alcohol, and drug use. The presence of a young adult’s own children and a spouse/partner is associated with a lower prevalence of most examined substance use patterns. As household compositions continue to diversify, targeted substance use prevention/treatment strategies may be needed.
- 14 August 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (8) , 1067
Open AccessHousehold Compositions and Substance Use among Young Adults in the U.S.
Background: Adults aged 21–29 have the highest past-month prevalence of tobacco, alcohol, and illicit drug use in the U.S. Currently, young adults often delay traditional adulthood milestones (e.g., marriage and childbearing), which may impact their household composition and substance use. Methods: We examined how the past-month prevalence of eight mutually exclusive substance use outcomes varied by household composition among young adults using the 2016–2019 National Surveys on Drug Use and Health (NSDUH) data. Bivariable and multivariable multinomial logistic regression analyses were applied. Results: Among young adults residing with their children, the most common household composition was residing with children and a spouse/partner (16.6%, 95% CI = 16.5–16.8%). Among those residing without children, common household compositions included residing with parents (22.8%, 95% CI = 22.2–23.4%) and residing only with a spouse/partner (17.9%, 95% CI = 17.6–18.3%). Past-month prevalence of binge alcohol, tobacco, and illicit drug use varied by household composition. Residing only with children and a spouse/partner was associated with a low prevalence of most examined substance use patterns. Across household compositions, those residing solely with unrelated individuals had the highest adjusted prevalence of tobacco, drug, and binge alcohol use (13.8%, 95% CI = 12.5–15.1%). Conclusions: The prevalence of substance use patterns among U.S. young adults varies by household composition. Those residing solely with unrelated individuals had the highest prevalence of tobacco, binge alcohol, and drug use. The presence of a young adult’s own children and a spouse/partner is associated with a lower prevalence of most examined substance use patterns. As household compositions continue to diversify, targeted substance use prevention/treatment strategies may be needed.
- 26 April 2024
- Published by Elsevier in International Journal of Drug Policy
- Vol. 128, 104431
Associations of cannabis use, use frequency, and cannabis use disorder with violent behavior among young adults in the United States
- 26 April 2024
- Published by Elsevier in International Journal of Drug Policy
- Vol. 128, 104431
Associations of cannabis use, use frequency, and cannabis use disorder with violent behavior among young adults in the United States
- Top Cited PapersOpen Access
- 22 September 2021
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 78 (12) , 1329-1342
Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults
In the US, overdose deaths involving psychostimulants with abuse potential other than cocaine (ie, largely methamphetamine) increased in the past decade1,2 more than doubling from 2.4 to 5.0 per 100 000 population from 2016 to 2019 alone.1 Furthermore, based on provisional mortality data, the estimated national number of these psychostimulant-associated overdose deaths increased 46% from 16 011 during November 2018 to October 2019 to 23 352 during November 2019 to October 2020.3
- 22 September 2021
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 78 (12) , 1329-1342
Top Cited PapersOpen AccessMethamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults
In the US, overdose deaths involving psychostimulants with abuse potential other than cocaine (ie, largely methamphetamine) increased in the past decade1,2 more than doubling from 2.4 to 5.0 per 100 000 population from 2016 to 2019 alone.1 Furthermore, based on provisional mortality data, the estimated national number of these psychostimulant-associated overdose deaths increased 46% from 16 011 during November 2018 to October 2019 to 23 352 during November 2019 to October 2020.3
- Top Cited PapersOpen Access
- 16 June 2021
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 78 (8) , 922-924
Use of Medications for Alcohol Use Disorder in the US
Treatment rates for alcohol use disorder (AUD) are low1 (eg, 7.6% in 20192). The US Food and Drug Administration has approved 4 evidence-based medications for treating AUD (MAUD) since 1949.3 To improve use of MAUD, the American Psychiatric Association released guidelines for pharmacological treatments of patients with AUD in 2017.4 However, little is known about prevalence and associations of using MAUD among US adults with AUD.
- 16 June 2021
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 78 (8) , 922-924
Top Cited PapersOpen AccessUse of Medications for Alcohol Use Disorder in the US
Treatment rates for alcohol use disorder (AUD) are low1 (eg, 7.6% in 20192). The US Food and Drug Administration has approved 4 evidence-based medications for treating AUD (MAUD) since 1949.3 To improve use of MAUD, the American Psychiatric Association released guidelines for pharmacological treatments of patients with AUD in 2017.4 However, little is known about prevalence and associations of using MAUD among US adults with AUD.
- 1 June 2021
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (6) , e2113025
Associations of Suicidality Trends With Cannabis Use as a Function of Sex and Depression Status
By April 2021, 15 US states and Washington, DC, had legalized nonmedical use of cannabis by adults, and 36 states and Washington, DC, had legalized medical use of cannabis. From 2008 to 2019, the number of adults with past-year cannabis use doubled from 22.6 million to 45.0 million. In parallel, the number of adults with cannabis use disorder (CUD) increased from 3.4 million to 4.1 million, and adults with daily or near-daily cannabis use (hereafter daily cannabis use) nearly tripled from 3.6 million to 9.8 million.1,2 During the same time frame, the number of adults with a past-year major depressive episode (MDE) increased from 14.5 million to 19.4 million, the number of adults with serious thoughts of suicide (hereafter referred to as suicidal ideation) increased from 8.3 million to 12.0 million,1,2 and the number of adults who died by suicide increased from 35 045 to 45 861.3
- 1 June 2021
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (6) , e2113025
Associations of Suicidality Trends With Cannabis Use as a Function of Sex and Depression Status
By April 2021, 15 US states and Washington, DC, had legalized nonmedical use of cannabis by adults, and 36 states and Washington, DC, had legalized medical use of cannabis. From 2008 to 2019, the number of adults with past-year cannabis use doubled from 22.6 million to 45.0 million. In parallel, the number of adults with cannabis use disorder (CUD) increased from 3.4 million to 4.1 million, and adults with daily or near-daily cannabis use (hereafter daily cannabis use) nearly tripled from 3.6 million to 9.8 million.1,2 During the same time frame, the number of adults with a past-year major depressive episode (MDE) increased from 14.5 million to 19.4 million, the number of adults with serious thoughts of suicide (hereafter referred to as suicidal ideation) increased from 8.3 million to 12.0 million,1,2 and the number of adults who died by suicide increased from 35 045 to 45 861.3
- Top Cited PapersOpen Access
- 1 June 2021
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 175 (6) , 640-643
Prevalence of Substance Use Disorders by Time Since First Substance Use Among Young People in the US
Earlier age at drug initiation has been shown to be associated with faster transition to substance use disorder (SUD).1 However, prevalence of specific SUDs as a function of time since first substance use among young people has not, to our knowledge, been investigated. We examined the prevalence of specific SUDs since first drug use (including tobacco, alcohol, cannabis, cocaine, methamphetamine, and heroin) or prescription misuse (including opioids, stimulants, and tranquilizers) in adolescents aged 12 to 17 years and young adults aged 18 to 25 years.
- 1 June 2021
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 175 (6) , 640-643
Top Cited PapersOpen AccessPrevalence of Substance Use Disorders by Time Since First Substance Use Among Young People in the US
Earlier age at drug initiation has been shown to be associated with faster transition to substance use disorder (SUD).1 However, prevalence of specific SUDs as a function of time since first substance use among young people has not, to our knowledge, been investigated. We examined the prevalence of specific SUDs since first drug use (including tobacco, alcohol, cannabis, cocaine, methamphetamine, and heroin) or prescription misuse (including opioids, stimulants, and tranquilizers) in adolescents aged 12 to 17 years and young adults aged 18 to 25 years.